Cegedim partners with Sanofi on RWE for healthcare in Europe

24 May 2019

Medical data provider Cegedim (Euronext: CGM) has announced a collaboration with French pharma major Sanofi (Euronext: SAN) to use real world evidence to improve healthcare in Europe.

Cegedim will deliver real world datasets with information going back to 1994, powered by its proprietary THIN (The Health Improvement Network) database, that covers the data of millions of patients from France, the UK, Spain, Belgium and Romania.

Datasets processed with artificial intelligence technologies will be analyzed by Cegedim and Sanofi’s data experts and medical teams. This collaboration aims to drive improvement in patient care in the Paris-based company’s numerous therapeutic areas.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK